A PHASE1/2, OPEN-LABEL, MULTI-CENTER, FIRST-IN-HUMAN SSTUDY OF THE SAFETY, TOLERABILLITY, PHARMACOKINETICS, AND ANTI-TUMOR AACTIVITY OF TPX-0005 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING ALK, ROS1, OR NTRK1-3 REARRANGEMENTS (TRIDENT-1)
2016-003616-13TUMORES SÓLIDOS AVANZADOSFundación Jiménez DíazInvestigador: MORENO GARCIA VICTOR
